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Abstract: Macrophages (Mf) are a versatile group of phagocytic cells responsible for fulfi lling a variety of 
immune functions, most notably for mounting the initial anti-microbial response and for the clearance of 
cellular debris and apoptotic bodies. Th e key processes for fulfi lling these functions include the produc-
tion of reactive oxygen intermediates (ROIs) and nitric oxide (NO). Mf also express a variety of receptors, 
including opioid, serotonin, and norepinephrine receptors, and thus can react to various substances. Our 
study aimed to examine the eff ects of oxycodone and buprenorphine on the production ROIs and NO by 
Mf from intraperitoneally-treated mice, as compared to the previously studied morphine, fentanyl, and 
methadone, as well as the eff ects of the analgesic adjuvants gabapentin, amitriptyline, and venlafaxine. 
ROIs was estimated via luminol and lucigenin dependent chemiluminescence assay, and NO secretion 
was estimated via a colorimetric method utilizing a modifi ed Griess reaction. We observed an overall 
decrease in both ROIs and NO production by Mf from adjuvant-treated mice, especially with amitriptyl-
ine. Opioids, however, resulted in enhanced ROIs production and mixed NO secretion, with oxycodone 
and buprenorphine have the least immunomodulatory eff ects. As ROIs and NO are potent mediators of 
Mf activity during the innate immune response, our current results express great translational potential. 
Our results suggest that OPs administration may boost Mf anti-microbial response. On the other hand, 
during sterile infl ammation, enhanced generation of ROIs by Mf infl uenced by opioids may increase the 
risk of tissue damage, but co-administration of adjuvants could abolish this adverse eff ect.
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Introduction
Macrophages (Mf) are a  versatile group of phagocytic cells responsible for fulfi lling 
a  variety of immune functions, most notably for mounting the initial anti-microbial 
response and for the clearance of cellular debris and apoptotic bodies. Th us, tissue 
resident Mf play an important role in innate immunity, as they are able either to activate 
and promote acute infl ammation against pathogen or to counteract immune response 
against self-antigens. Additionally, Mf function as antigen presenting and eff ector 
cells, helping to induce the adaptive, humoral, and cellular immune response  [1–2]. 
Due to their ability to release various pro and anti-infl ammatory mediators, Mf  also 
contribute to the orchestration and regulation of immune mechanisms, and their 
cytotoxic activation is observed in delayed-type hypersensitivity (DTH), including the 
cutaneous contact sensitivity (CS) reaction. Th e key processes for fulfi lling this variety 
of functions include the production of reactive oxygen intermediates (ROIs) and nitric 
oxide (NO)  [3–5]. It is also notable that Mf express a  variety of cell-membrane-
-associated and intracellular receptors, including opioid, serotonin, and norepinephrine 
receptors [6–11]. Th us, these cells can react to numerous signaling molecules, including 
cytokines, hormones, neurotransmitters and bioactive compounds of diff erent 
medications [12]. 
As mentioned above, Mf cytotoxic activity is facilitated mostly by the release 
of reactive oxygen intermediates (ROIs) and nitric oxide (NO). When induced 
by pathogen infection, ROIs and NO are potent microbicidal agents that favor the 
activation of acute infl ammation. However, during chronic or sterile infl ammation, 
Mf-derived oxygen and nitrogen radicals could exacerbate the oxidative stress 
responsible for tissue damage and oxidative modifi cations of self-proteins and lipids. 
On the other hand, during the adaptive immune response, secreted NO greatly 
increases Mf cytotoxic activity against intracellular pathogens inducing DTH, 
and together with ROIs, could regulate immune mechanisms through induction 
of eff ector T cell apoptosis and stimulation of regulatory T cell function [13]. Th e 
zymosan-stimulated generation of ROIs by Mf can be measured in vitro in the 
luminol and lucigenin dependent chemiluminescence assay. As luminol may cross 
cellular membranes, it can be oxidized by both extra- and intracellular pools of ROIs 
to emit luminescence, while lucigenin is oxidized only by extracellularly secreted 
ROIs [13, 14]. Further, the concentration of NO secreted to culture medium by Mf 
stimulated with bacterial LPS can be measured in a  colorimetric method based on 
Griess reaction.
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Opioid titration is a common procedure in the management of unrelieved pain. In 
some instances, increasing the opioid dose leads to a paradoxical intensifi cation of the 
pain experience. Th is phenomenon is named opioid hyperalgesia [15]. Additionally, 
opioid drug treatment of neuropathic pain is signifi cantly less eff ective, since their 
analgesic action appears later than exerted severe adverse eff ects. Accordingly, the use 
of analgesic adjuvants (AAs) should be considered for the alleviation of uncontrolled 
pain, especially of a  neuropathic nature [16] and for mitigation of opioid-induced 
hyperalgesia [15]. Th e adjuvant amplifi cation of opioid action has already been shown 
in the case of some of antidepressants and anticonvulsants. Analgesic properties 
of opioids but also AAs, among other things depend on their direct infl uence on 
function of immune cells. Targeting of macrophages by analgesic drugs could be the 
most eff ective. 
Filipczak-Bryniarska et al. previously showed enhancement of ROIs production 
in mice treated with opioids (OPs), such as morphine, fentanyl, and methadone [14]. 
Yet, little has been demonstrated regarding the immunological effects of two 
other commonly used OPs, namely oxycodone and buprenorphine. Oxycodone 
is a  commonly used opioid, which acts mainly as a  μ-receptor agonist, but is also 
believed to have some κ-receptor activity [17–19]. Buprenorphine is a semisynthetic, 
highly lipophilic opioid, about 30 times stronger than morphine, which acts as 
a μ-receptor agonist, as well as a κ-receptor antagonist [17, 19, 20]. 
In the palliative care setting, OPs are oft en administered with AAs. AAs are drugs, 
which are not expressly indicated to treat pain, but have been found to be useful in 
certain clinical situations, such as in the treatment of neuropathic pain [19]. Some of 
the most commonly used AAs include anticonvulsants, such as gabapentin (GABA); 
tricyclic antidepressants, such as amitriptyline (AMI); and serotonin-norepinephrine 
reuptake inhibitors, such as venlafaxine (VENLA). While the analgesic effi  cacy of OPs 
and AAs is well established, much remains to be elucidated about their eff ects on the 
immune system [19, 21].
Our study aimed to examine the eff ects of oxycodone and buprenorphine on 
the production ROIs and NO by murine Mf, as compared to the previously studied 
morphine, fentanyl, and methadone, as well as the effects of GABA, AMI, and 
VENLA, both independently and with co-administration of the prototypic opioid 
morphine.
Materials and methods
Animals
For this study, we used inbred male CBA/J mice, ranging from eight to ten weeks old, 
which were procured from the Animal Facility of the Faculty of Medicine, Jagiellonian 
University Medical College, Krakow, Poland. All animal subjects were given free 
18 Michael Kozlowski, Katarzyna Nazimek, et al.
access to food and water. All experiments were conducted according to the guidelines 
of the Animal Care and Use Committee of the Jagiellonian University Medical College 
and under ethical approval of the 1st Local Ethics Committee (approval no. 102/2009, 
123/2013, 215/2015).
Drugs
The following opioid drugs were used: buprenorphine (01AF0512), fentanyl 
(06BC0815), morphine sulfate (02DR0910), naloxone hydrochloride (02BZ0514) 
(WZF Polfa SA, Warsaw, Poland), methadone hydrochloride (Molteni Farmaceutici 
Polska), oxycodone hydrochloride (AB465, Mundipharma Polska Sp. z o.o., Warsaw, 
Poland). Th e following analgesic adjuvant drugs were also used: amitriptyline 
hydrochloride (A8404), gabapentin (G154) and venlafaxine hydrochloride (V7264) 
(Sigma, St. Louis, MO, USA). All drugs were used as sterile solutions in DPBS for 
intraperitoneal injections.
Reagents
Th e following reagents were used: acetone, ethanol, glucose, reagent kit for Griess 
reaction, trypan blue (POCh SA, Gliwice, Poland), Dulbecco’s phosphate-buff ered 
saline (DPBS), fetal calf serum (FCS), Pen-Strep, RPMI1640 (Gibco Life Technologies, 
Grand Island, NY, USA), dimethyl sulfoxide (DMSO), heparin sodium salt, 
lucigenin (bis-methylacridinum nitrate), luminol (3-aminophthalic hydrazide), 
2-mercaptoethanol (2-ME), mineral oil (heavy fraction), TRIS buff er, zymosan (freshly 
opsonized with mouse serum) (Sigma, St. Louis, MO, USA) and lipopolysaccharide 
(LPS) (BIO-Whittaker, Walkersville, MD).
Experimental design
Th is study was divided into two sets of experiments, the fi rst involving only OPs and 
the second involving morphine (as the most studied opioid representative) and AAs. 
Oil-induced peritoneal Mf were harvested from mouse donors, who had been treated 
intraperitoneally (i.p.) with OPs and/or AAs. In the fi rst group of experiments, mice 
were treated for seven days with the following drugs: morphine at a dose of 20 mg/kg 
twice per 24 h, fentanyl 10 mg/kg twice per 24 h, methadone 30 mg/kg once per 24 h, 
oxycodone 20 mg/kg twice per 24 h, buprenorphine 2 mg/kg once per  24  h, and 
naloxone 1 mg/kg once per 24 h. In the second group of experiments, mice were 
treated for eight days with morphine; morphine and naloxone; AMI; AMI and 
morphine; GABA; GABA and morphine; VENLA; or VENLA and morphine. Dosages 
were as follows: morphine 20 mg/kg twice per 24 h, naloxone 1 mg/kg once per 24 h, 
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AMI 10 mg/kg once per 24 h, GABA 5 mg/kg once per 24 h, VENLA 5 mg/kg once 
per 24 h. In both cases some mice did not receive any medicaments and were used as 
a control. Mf were induced by the i.p. injection of 1 ml of mineral oil on day 2 for the 
OPs-only group of experiments and on day 3 for the morphine and AAs group. 
Harvesting of oil-induced peritoneal Mf
Mf were harvested from peritoneal cavities of mice 5 days aft er injection with mineral 
oil. Each treatment group was represented by Mf from 3 to 6 mice. Mf were washed 
out of peritoneal cavities with 5 ml of ice-cold DPBS containing heparin (5 U/ml) 
and, aft er control of their viability, used for in vitro studies. 
Measurements of ROIs production
Th e production of ROIs by Mf from mice in all treatment groups, as well as from 
control mice, was analyzed by a  luminol-dependent and lucigenin-dependent 
chemiluminescence assay. Mf from all treatment and control groups were added 
to 96-well fl at bottom dark plates at a  concentration of 5 × 105 viable cells/well in 
0.2 ml RPMI1640 medium supplemented with 10% FCS. Chemiluminescence probes 
were then added and Mf were incubated in darkness for 15 min at 37°C. Mouse 
serum-opsonized zymosan was subsequently added to selected wells, and plates 
were immediately transferred to a  Lucy 1 luminometer (Anthos, Salzburg, Austria). 
Th e measurement of luminescence lasted for 75 min. Each measurement was 
completed twice.
Measurement of nitric oxide concentration
Mf from the various treatment and control groups were placed in wells of 24-well plate 
at a concentration of 5 × 105/ml in RPMI1640 medium supplemented with 5% FCS and 
cultured in 5% CO2 at a  temperature of 37°C. Lipopolysaccharide (LPS) was added to 
some wells to achieve a concentration of 100 ng/ml. Supernatants for NO measurement 
were collected aft er 24 h of culture. Concentrations of NO were immediately measured 
via a colorimetric method utilizing a modifi ed Griess reaction [13].
Results
Eff ect of OPs on zymosan-induced ROIs production
When measuring extracellular ROIs generation using lucigenin, which is too large to 
enter Mf [22, 23], we observed a signifi cant increase in ROIs production by Mf isolated 
from mice treated with OPs, in particular fentanyl (peak about 6,500), buprenorphine 
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(a)
(b)
Fig. 1. Th e infl uence of opioid administration on the production of reactive oxygen intermediates (ROIs) 
by macrophages. Oil-induced peritoneal macrophages from mice treated for seven days with each 
respective opioid were incubated at 37°C for 15 min with a  chemiluminescence probe, either lucigenin 
(a) or luminol (b), on 96-well fl at bottom dark plates at a  concentration of 5 × 105 viable cells/well in 
0.2 ml RPMI1640 medium supplemented with 10% FCS. Samples were subsequently stimulated with 
zymosan and the kinetics of ROIs production was measured via chemiluminescence measurement in 
a luminometer. Results are expressed in relative unites of luminescence emission (RULE) per second.
Mf ctrl: untreated control macrophages; Mf MF: macrophages from mice treated with morphine; 
Mf MF/NALOX: macrophages from mice treated with morphine and naloxone; Mf BPNF: macrophages 
from mice treated with buprenorphine; Mf FENT: macrophages from mice treated with fentanyl; Mf 
METH: macrophages from mice treated with methadone; Mf OXCD: macrophages from mice treated 
with oxycodone.
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(peak about 5,750), and oxycodone (peak about 4,800), when compared to 
production by Mf from control mice (peak about 2,400) (Fig. 1a). When measuring 
extra- and intracellular ROIs generation using luminol, which is able to cross cell 
membranes  [22,  23], we again observed a  signifi cant increase in their production by 
Mf isolated from mice treated with OPs, when compared to production by Mf from 
control mice (peak about 19,000) (Fig. 1b). Fentanyl and buprenorphine were again 
the most stimulatory. Interestingly, we observed decreased total ROIs production by 
Mf from mice who had received oxycodone (peak about 15,500) when compared 
to control mice. Notably, Mf from mice treated with naloxone solely expressed 
signifi cantly weakened production of ROIs in comparison to Mf from drug-untreated 
or morphine-treated mice. Similarly, Mf from mice treated with morphine + naloxone 
showed decreased ROIs production when compared to Mf from morphine-treated 
donors. 
Eff ect of AAs on zymosan-induced ROIs production
When measuring extracellular ROIs generation using lucigenin, we observed 
a  signifi cant decrease in ROIs production by Mf isolated from mice treated with 
AAs, particularly from mice treated solely with amitriptyline (peak about 4,500) 
and venlafaxine (peak about 5,000), as compared to Mf from mice treated with 
morphine (peak about 6,500) (Fig. 2a). Quite intriguing was our observation that Mf 
from mice who received morphine + AA showed decreased production of ROIs in 
comparison with Mf from morphine-treated donors, and in the case of Mf from mice 
administered with morphine + amitriptyline even when compared with control Mf. 
When measuring total ROIs generation using luminol, we observed a similar decrease 
in peak ROIs production from AA-treated mice, as compared to morphine-treated 
animals (Fig. 2b). Furthermore, co-treatment of Mf donors with morphine + AA again 
resulted in reduced generation of total pool of ROIs by Mf when compared to eff ects 
of treatment with morphine alone. Th e greatest decrease was also seen in mice treated 
with morphine + amitriptyline (peak about 18,000), when compared to mice who 
received only morphine (peak about 32,000). However, total peak ROIs production 
by these Mf was higher than in control Mf. As above, an analogous inhibitory eff ect 
on ROIs generation was shown in the case of Mf from donors administered with 
morphine + naloxone, when compared to morphine-treated donor Mf.
Eff ect of OPs on NO secretion
When estimating the concentration of NO in supernatants from cultures of 
LPS-stimulated Mf from mice treated with OPs, we observed some quite interesting 
results (Table 1). We demonstrated an increased concentration of NO in samples of 
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Fig. 2. Th e infl uence of analgesic adjuvant administration on the production of reactive oxygen 
intermediates (ROIs) by macrophages. Oil-induced peritoneal macrophages from mice treated for seven 
days with each analgesic adjuvant, with or without co-administration of morphine, were incubated 
at 37°C for 15 min with a  chemiluminescence probe, either lucigenin (a) or luminol (b), on 96-well 
fl at bottom dark plates at a  concentration of 5 × 105 viable cells/well in 0.2 ml RPMI1640 medium 
supplemented with 10% FCS. Samples were subsequently stimulated with zymosan and the kinetics of 
ROIs production was measured via chemiluminescence measurement in a  luminometer. Results are 
expressed in relative unites of luminescence emission (RULE) per second.
Mf ctrl: untreated control macrophages; Mf MF: macrophages from mice treated with morphine; Mf MF/
NALOX: macrophages from mice treated with morphine and naloxone; Mf AMI: macrophages from mice 
treated amitriptyline; Mf MF/AMI: macrophages from mice treated with morphine and amitriptyline; 
Mf GABA: macrophages from mice treated with gabapentin; Mf MF/GABA: macrophages from mice 
treated with morphine and gabapentin; Mf VENLA: macrophages from mice treated with venlafaxine; 
Mf MF/VENLA: macrophages from mice treated with morphine and venlafaxine.
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Mf isolated from mice treated with morphine and buprenorphine, but we observed 
a greatly decreased concentration in those of mice treated with fentanyl, methadone, 
and oxycodone. Th is pattern was also seen in the concentration of unstimulated 
samples, with the exception of morphine-treated mice, whose Mf exhibited a decreased 
NO concentration compared to those of control mice. In addition, Mf from mice 
treated with morphine + naloxone released less NO than those from donors treated 
with morphine alone and its supernatant concentration was comparable to this of 
control Mf. 
Table 1. Th e infl uence of opioids on nitric oxide secretion by macrophages.
Group Unstimulated Mf[105/mL]
Mf stimulated in vitro with LPS
[100 ng/mL]
Mf ctrl 5.6 ± 0.3 17.20 ± 0.4
Mf MF 2.1 ± 0.3 26.90 ± 4.2
Mf MF/NALOX 3.6 ± 0.3 17.70 ± 2.3
Mf NALOX 4.5 ± 1.4 15.20 ± 1.8
Mf BPNF 7.5 ± 2.0 20.80 ± 2.1
Mf FENT 1.7 ± 0.1  2.04 ± 0.1
Mf METH 1.8 ± 0.2  4.54 ± 1.2
Mf OXCD 3.8 ± 0.1  9.40 ± 0.4
Oil-induced peritoneal macrophages from mice treated for seven days with each respective opioid were placed 
in wells of a  24-well plate at a  concentration of 5 × 105/ml in RPMI1640 medium supplemented with 5% FCS 
and cultured in 5% CO2 at a  temperature of 37°C. Lipopolysaccharide (LPS) was added to some wells to achieve 
a  concentration of 100 ng/ml. Supernatants for nitric oxide measurement were collected aft er 24 h of culture. 
Concentrations of NO were immediately measured via a colorimetric method utilizing a modifi ed Griess reaction. 
Nitric oxide concentrations are expressed in μM.
Mf ctrl: untreated control macrophages; Mf MF: macrophages from mice treated with morphine; Mf MF/NALOX: 
macrophages from mice treated with morphine and naloxone; Mf BPNF: macrophages from mice treated with 
buprenorphine; Mf FENT: macrophages from mice treated with fentanyl; Mf METH: macrophages from mice 
treated with methadone; Mf OXCD: macrophages from mice treated with oxycodone.
Eff ects of AAs on NO secretion
When unstimulated with LPS, all AA-treated groups showed a  decreased basal 
secretion of NO compared to the control group (Table 2). When stimulated with LPS, 
we observed a  signifi cantly decreased secretion in groups of Mf from mice treated 
with amitriptyline, morphine + amitriptyline, gabapentin and morphine + gabapentin. 
Interestingly, we observed an increased secretion by Mf from mice treated 
with venlafaxine + morphine, and a  secretion comparable to control Mf from 
venlafaxine-treated animals.
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Table 2. Th e infl uence of analgesic adjuvants on nitric oxide secretion by macrophages.
Group Unstimulated Mf[105/mL]
Mf stimulated in vitro with LPS 
[100 ng/mL]
Mf ctrl 5.6 ± 0.30 17.2 ± 0.4
Mf MF 2.1 ± 0.30 26.9 ± 4.2
Mf MF/NALOX 3.6 ± 0.30 17.7 ± 2.3
Mf AMI 0.0 ± 0.00  3.0 ± 2.5
Mf MF/AMI 0.0 ± 0.00  4.0 ± 1.0
Mf GABA 0.0 ± 0.00  7.0 ± 2.0
Mf MF/GABA 0.0 ± 0.20 12.0 ± 1.5
Mf VENLA 0.1 ± 0.05 17.1 ± 2.1
Mf MF/VENLA 3.8 ± 0.10 24.0 ± 3.2
Oil-induced peritoneal macrophages from mice treated for seven days with each respective analgesic adjuvant, 
with or without co-administration of morphine, were placed in wells of a  24-well plate at a  concentration of 
5 × 105/ml in RPMI1640 medium supplemented with 5% FCS and cultured in 5% CO2 at a  temperature of 
37°C. Lipopolysaccharide (LPS) was added to some wells to achieve a  concentration of 100  ng/ml. Supernatants 
for nitric oxide measurement were collected aft er 24  h of culture. Concentrations of NO were immediately 
measured via a  colorimetric method utilizing a  modifi ed Griess reaction. Nitric oxide concentrations are 
expressed in μM.
Mf ctrl: untreated control macrophages; Mf MF: macrophages from mice treated with morphine; Mf MF/
NALOX: macrophages from mice treated with morphine and naloxone; Mf AMI: macrophages from mice 
treated amitriptyline; Mf MF/AMI: macrophages from mice treated with morphine and amitriptyline; Mf GABA: 
macrophages from mice treated with gabapentin; Mf MF/GABA: macrophages from mice treated with morphine 
and gabapentin; Mf VENLA: macrophages from mice treated with venlafaxine; Mf MF/VENLA: macrophages 
from mice treated with morphine and venlafaxine.
Discussion
Current results showed that week-long treatment of mice with OPs, such as morphine, 
buprenorphine, fentanyl and methadone, led to the enhancement of ROIs generation 
by Mf activated with zymosan, a fungal pathogen-associated molecular pattern (PAMP) 
bearing inducer of Mf oxidative burst, as well as a potent infl ammatory response [24]. 
In the case of oxycodone administration, it resulted in the enhancement of generation 
of extracellular ROIs, while total ROIs production by Mf was slightly reduced. Th e 
increase of ROIs generation by Mf induced by morphine treatment was restrained 
by co-administration of naloxone with morphine. Importantly, co-administration 
of AAs, such as amitriptyline, gabapentin and venlafaxine, together with morphine 
also potently moderated the increase of ROIs production by Mf observed as a  result 
of morphine action. In a  similar manner, Mf from mice treated with morphine and 
buprenorphine secreted more NO in a response to LPS stimulation, and this eff ect was 
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again reversed by co-administration of naloxone together with morphine. However, 
LPS-stimulated Mf from animals treated with fentanyl, methadone, and oxycodone 
were characterized by inhibited release of NO. Importantly, both co-treatment of 
mice with morphine together with AAs or with AAs solely, also led to a  signifi cant 
reduction of NO release by Mf.
As ROIs and NO are potent mediators of Mf activity in the innate immune 
response, our current results express great translational potential. Accordingly, it 
could be speculated that OPs administration may boost Mf anti-microbial response. 
On the other hand, during sterile inflammation, enhanced generation of ROIs 
by Mf influenced by opioid drugs may increase the risk of tissue damage, and 
co-administration of AAs could likely negate this adverse eff ect.
However, during sterile inflammation, ROIs secreted by Mf were also shown 
to control and fi nally diminish the active immune response by targeting eff ector  T 
lymphocytes, which leads to the inhibition of their differentiation along with 
induction of their apoptosis [25]. Further, this ROIs-mediated mechanism of immune 
response restriction additionally promotes the survival of memory T cells  [25]. 
Importantly, due to the very short biological half-life of ROIs, their activity is 
limited to cells in close proximity to Mf [26], especially those forming the immune 
synapse [26, 27]. ROIs-mediated eff ects may either signifi cantly aff ect intracellular 
signalization pathways [28], or, along with cytokine-induced eff ects, might activate 
the eff ector response at the immune synapse [29]. Th us, our current observations 
suggest that OPs-induced eff ects on ROIs generation by Mf may facilitate both the 
activation of cells at the immune synapse and the naturally occurring process of 
limitation of the immune response to the required time and intensity. Interestingly, 
mice with genetically restricted ROIs defi ciency were shown to express enhanced risk 
of developing an autoimmune response [30]. Accordingly, the protective eff ects of 
ROIs generated by Mf in the course of rheumatoid arthritis was demonstrated to be 
associated with the activation of regulatory T lymphocytes [31, 32]. Th erefore, OPs 
administration could augment the benefi cial eff ects of Mf-derived ROIs in prevention 
of autoimmune responses through the activation of regulatory cells.
Mf-derived NO was also identifi ed as a  potent regulator of immune response, 
involved in the suppression of T cell-depen dent immunity [33–36], including the 
CS reaction [37]. Thus, while treatment with morphine or buprenorphine may 
additionally support the restriction of excessive inflammatory and allergic or 
hypersensitive response by enhancing NO production by Mf, administration of other 
OPs, especially together with AAs, may impair the regulation of the T cell-mediated 
immune response. 
Of clinical interest, the production of ROIs and NO are essential processes 
performed by Mf during the innate immune response. Th eir production assists Mf 
in fulfi lling a  variety of functions, ranging from the killing of microbes to antigen 
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processing [1–4]. While being invaluable for the proper functioning of the immune 
system, their overproduction has also been implicated in a  number of harmful 
processes, including the cachexia-anorexia syndrome (CAS) [19, 38–40]. CAS is 
characterized clinically by the involuntary loss of fat and muscle tissue, as well as loss of 
appetite [19]. Although the pathophysiology of this syndrome is not fully understood, 
it is thought to result from generalized hormonal and immune dysfunction. Several 
specific immune-related substances are implicated in its pathogenesis, including 
ROIs. Other animal studies have implicated ROIs and NO in muscle damage 
and wasting [41–43]. Furthermore, some clinical studies in humans have found 
antioxidant treatment to be effective in limiting muscle wasting among cancer 
patients [44]. 
Th e results of our study suggest a strong enhancement of the production of ROIs 
by Mf from mice treated with OPs, which is in line with previous research [14]. It 
is important to note that OPs are necessary for pain control in up to two-thirds of 
patients suffering from advanced neoplastic disease [19]. These advanced cancer 
patients are also the most at risk for the development of CAS. However, our study also 
found that the addition of an AA to OPs treatment greatly limited the enhancement 
of ROIs production. Th is was particularly pronounced in the case of amitriptyline. 
We also found that AAs led to a lower basal secretion of NO, and amitriptyline led to 
decreased NO secretion even when Mf were stimulated with LPS. Based upon these 
observations, AAs may be benefi cial additions to the treatment regimen of patients 
receiving OPs, especially those suff ering from or at risk of cachexia. Further studies 
are warranted to investigate their therapeutic potential, with amitriptyline being 
a particularly suitable candidate for further investigation.
Tricyclic antidepressants, herein represented by amitriptyline, act as serotonin 
re-uptake inhibitors, similarly to venlafaxine, which additionally blocks norepinephrine 
re-uptake. As macrophages express receptors for serotonin and norepinephrine, they 
can sense the clinically eff ective increase in the concentration of neurotransmit-
ters  [45]. Th us, it could be suspected that neurotransmitter-induced eff ects are also 
involved in immune-mediated analgesia by antidepressant AAs. Further, the inhibition 
of macrophage release of proinfl ammatory cytokines, such as IL-6 and TNFα, was 
recently demonstrated as a result of venlafaxine and imipramine administration [46]. 
As these cytokines strongly contribute to the immune inducing mechanisms of severe 
neuropathic pain, their inhibition likely expresses an analgesic eff ect that could also 
be responsible for the antidepressant action of AAs.
Th e anticonvulsant gabapentin ameliorates pathological signaling through the 
ion channels. It binds to the G protein of voltage-dependent calcium channel, 
which leads to pain relieving cell hyperpolarization. Th is eff ect of gabapentin was 
recently shown to reverse proinfl ammatory activation of macrophages observed in 
chemotherapy-induced peripheral neuropathy [47]. Similarly, our current results 
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show that co-treatment with morphine and gabapentin reduced the oxidative burst of 
macrophages strengthened by treatment with morphine alone. 
In conclusion, it seems to be important to point out that, in comparison to 
morphine, buprenorphine and oxycodone express weaker immunomodulatory 
properties, avoiding redundant suppression of physiological immune defense. 
Increasing opioid doses oft en is insuffi  cient and can produce hyperalgesia in the 
treatment of severe pain. Thus, the addition of AAs to opioid therapy, facilitating 
immune mechanisms responsible for pain relief, possesses great clinical importance. 
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